Table of Contents
Chemotherapy Research and Practice
Volume 2015 (2015), Article ID 512016, 4 pages
http://dx.doi.org/10.1155/2015/512016
Research Article

Oral Antineoplastic Agents: Assessing the Delay in Care

1Wake Forest Baptist Health, Medical Center Boulevard, Winston-Salem, NC 27157, USA
2West Virginia University Healthcare, 1 Medical Center Drive, Morgantown, WV 26506, USA
3Clinical Department, West Virginia University School of Pharmacy, Morgantown, WV 26506, USA

Received 29 May 2015; Accepted 5 October 2015

Academic Editor: Tadeusz Robak

Copyright © 2015 Brandi Anders et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Leveque, A. Delpeuch, and B. Gourieux, “New anticancer agents: role of clinical pharmacy services,” Anticancer Research, vol. 34, no. 4, pp. 1573–1578, 2014. View at Google Scholar · View at Scopus
  2. G. L. Banna, E. Collovà, V. Gebbia et al., “Anticancer oral therapy: emerging related issues,” Cancer Treatment Reviews, vol. 36, no. 8, pp. 595–605, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. S. N. Weingart, E. Brown, P. B. Bach et al., “NCCN task force report: oral chemotherapy,” Journal of the National Comprehensive Cancer Network, vol. 6, supplement 3, pp. S1–S14, 2008. View at Google Scholar
  4. S. B. Streeter, L. Schwartzberg, N. Husain, and M. Johnsrud, “Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions,” Journal of Oncology Practice, vol. 7, supplement 3, pp. 46S–51S, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. CenterWatch, FDA Approved Drugs by Therapeutic Area. FDA Approved Drugs for Hematology, January 2014, http://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/6/hematology.
  6. CenterWatch, “FDA Approved Drugs by Therapeutic Area. FDA Approved Drugs for Oncology,” 2014, http://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology.
  7. D. A. McCue, L. K. Lohr, and A. M. Pick, “Improving adherence to oral cancer therapy in clinical practice,” Pharmacotherapy, vol. 34, no. 5, pp. 481–494, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Bowman, A. Rousseau, D. Silk, and C. Harrison, “Access to cancer drugs in medicare part D: formulary placement and beneficiary cost sharing in 2006,” Health Affairs, vol. 25, no. 5, pp. 1240–1248, 2006. View at Publisher · View at Google Scholar · View at Scopus